Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.22
GSK's Cash to Debt is ranked higher than
51% of the 904 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.48 vs. GSK: 0.22 )
GSK' s 10-Year Cash to Debt Range
Min: 0.02   Max: No Debt
Current: 0.22

Equity to Asset 0.13
GSK's Equity to Asset is ranked lower than
53% of the 820 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.59 vs. GSK: 0.13 )
GSK' s 10-Year Equity to Asset Range
Min: 0.05   Max: 0.4
Current: 0.13

0.05
0.4
Interest Coverage 9.68
GSK's Interest Coverage is ranked higher than
57% of the 551 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 101.95 vs. GSK: 9.68 )
GSK' s 10-Year Interest Coverage Range
Min: 0.81   Max: 28.06
Current: 9.68

0.81
28.06
F-Score: 6
Z-Score: 2.21
M-Score: -2.50
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 22.54
GSK's Operating margin (%) is ranked higher than
92% of the 857 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.59 vs. GSK: 22.54 )
GSK' s 10-Year Operating margin (%) Range
Min: 1.68   Max: 36.94
Current: 22.54

1.68
36.94
Net-margin (%) 17.63
GSK's Net-margin (%) is ranked higher than
91% of the 857 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.31 vs. GSK: 17.63 )
GSK' s 10-Year Net-margin (%) Range
Min: 5.76   Max: 23.94
Current: 17.63

5.76
23.94
ROE (%) 68.04
GSK's ROE (%) is ranked higher than
99% of the 874 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.83 vs. GSK: 68.04 )
GSK' s 10-Year ROE (%) Range
Min: 17.3   Max: 244.21
Current: 68.04

17.3
244.21
ROA (%) 10.35
GSK's ROA (%) is ranked higher than
91% of the 910 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.02 vs. GSK: 10.35 )
GSK' s 10-Year ROA (%) Range
Min: 3.84   Max: 26.32
Current: 10.35

3.84
26.32
ROC (Joel Greenblatt) (%) 58.14
GSK's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 904 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.17 vs. GSK: 58.14 )
GSK' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 5.44   Max: 141.62
Current: 58.14

5.44
141.62
Revenue Growth (%) -0.90
GSK's Revenue Growth (%) is ranked higher than
62% of the 738 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.60 vs. GSK: -0.90 )
GSK' s 10-Year Revenue Growth (%) Range
Min: -1.5   Max: 15.3
Current: -0.9

-1.5
15.3
EBITDA Growth (%) 17.60
GSK's EBITDA Growth (%) is ranked higher than
82% of the 694 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.60 vs. GSK: 17.60 )
GSK' s 10-Year EBITDA Growth (%) Range
Min: -12.1   Max: 17.6
Current: 17.6

-12.1
17.6
EPS Growth (%) 51.40
GSK's EPS Growth (%) is ranked higher than
94% of the 665 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. GSK: 51.40 )
GSK' s 10-Year EPS Growth (%) Range
Min: -30.2   Max: 51.4
Current: 51.4

-30.2
51.4
» GSK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

GSK Guru Trades in Q4 2013

Francis Chou 18,000 sh (New)
Joel Greenblatt 83,452 sh (New)
John Hussman 423,500 sh (+1702.13%)
John Rogers 421,201 sh (+208.93%)
Jim Simons 6,425,000 sh (+65.11%)
Charles Brandes 2,145,461 sh (+13.11%)
Ken Fisher 11,126,274 sh (+0.06%)
Murray Stahl 23,723 sh (unchged)
Diamond Hill Capital 11,561 sh (unchged)
Jean-Marie Eveillard 1 sh (unchged)
Warren Buffett Sold Out
Steven Cohen Sold Out
Jeff Auxier 112,170 sh (-0.49%)
Tweedy Browne 150,184 sh (-0.56%)
PRIMECAP Management 9,998,877 sh (-0.79%)
NWQ Managers 209,325 sh (-1.17%)
Dodge & Cox 60,479,650 sh (-1.32%)
Manning & Napier Advisors, Inc 383,698 sh (-4.11%)
Vanguard Health Care Fund 644,881 sh (-55.18%)
» More
Q1 2014

GSK Guru Trades in Q1 2014

Louis Moore Bacon 75,000 sh (New)
Steven Cohen 5,921 sh (New)
HOTCHKIS & WILEY 36,773 sh (New)
Bill Frels 4,496 sh (New)
Diamond Hill Capital 190,984 sh (+1551.97%)
John Rogers 662,150 sh (+57.21%)
Jim Simons 7,009,800 sh (+9.1%)
Charles Brandes 2,164,241 sh (+0.88%)
Ken Fisher 11,214,364 sh (+0.79%)
Murray Stahl 23,792 sh (+0.29%)
Joel Greenblatt 83,452 sh (unchged)
Francis Chou 18,000 sh (unchged)
Jean-Marie Eveillard 1 sh (unchged)
Vanguard Health Care Fund Sold Out
Dodge & Cox 60,386,550 sh (-0.15%)
Jeff Auxier 109,170 sh (-2.67%)
Tweedy Browne 142,598 sh (-5.05%)
PRIMECAP Management 9,177,877 sh (-8.21%)
Manning & Napier Advisors, Inc 329,053 sh (-14.24%)
John Hussman 323,500 sh (-23.61%)
NWQ Managers 148,800 sh (-28.91%)
» More
Q2 2014

GSK Guru Trades in Q2 2014

James Barrow 270,900 sh (New)
Pioneer Investments 93,226 sh (New)
HOTCHKIS & WILEY 4,949,118 sh (+13358.6%)
John Rogers 988,772 sh (+49.33%)
Jim Simons 8,869,400 sh (+26.53%)
Charles Brandes 2,500,048 sh (+15.52%)
Ken Fisher 11,365,903 sh (+1.35%)
Murray Stahl 23,992 sh (+0.84%)
Manning & Napier Advisors, Inc 331,544 sh (+0.76%)
Joel Greenblatt 83,528 sh (+0.09%)
NWQ Managers 148,850 sh (+0.03%)
John Hussman 323,500 sh (unchged)
Jean-Marie Eveillard 1 sh (unchged)
Francis Chou 18,000 sh (unchged)
Louis Moore Bacon Sold Out
Dodge & Cox 60,226,050 sh (-0.27%)
Tweedy Browne 142,118 sh (-0.34%)
Jeff Auxier 108,620 sh (-0.5%)
Diamond Hill Capital 189,641 sh (-0.7%)
Bill Frels 3,846 sh (-14.46%)
PRIMECAP Management 5,156,449 sh (-43.82%)
» More
Q3 2014

GSK Guru Trades in Q3 2014

David Dreman 1,328 sh (New)
Irving Kahn 51,000 sh (New)
Pioneer Investments 331,758 sh (+255.86%)
HOTCHKIS & WILEY 10,804,564 sh (+118.31%)
NWQ Managers 208,125 sh (+39.82%)
Charles Brandes 3,415,717 sh (+36.63%)
Jeff Auxier 133,518 sh (+22.92%)
John Rogers 1,005,634 sh (+1.71%)
Ken Fisher 11,488,594 sh (+1.08%)
Manning & Napier Advisors, Inc 333,460 sh (+0.58%)
Murray Stahl 24,022 sh (+0.13%)
Francis Chou 18,000 sh (unchged)
Louis Moore Bacon 300,000 sh (unchged)
John Hussman 323,500 sh (unchged)
Jean-Marie Eveillard 1 sh (unchged)
James Barrow 270,900 sh (unchged)
Bill Frels Sold Out
Joel Greenblatt 83,462 sh (-0.08%)
Tweedy Browne 140,278 sh (-1.29%)
PRIMECAP Management 4,874,635 sh (-5.47%)
Jim Simons 6,827,600 sh (-23.02%)
Dodge & Cox 38,589,161 sh (-35.93%)
Diamond Hill Capital 14,902 sh (-92.14%)
» More
» Details

Insider Trades

Latest Guru Trades with GSK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Dodge & Cox 2014-09-30 Reduce -35.93%1.11%$46.29 - $54.52 $ 46.4-5%38589161
HOTCHKIS & WILEY 2014-09-30 Add 118.31%0.98%$46.29 - $54.52 $ 46.4-5%10804564
Charles Brandes 2014-09-30 Add 36.63%0.56%$46.29 - $54.52 $ 46.4-5%3415717
Irving Kahn 2014-09-30 New Buy0.38%$46.29 - $54.52 $ 46.4-5%51000
NWQ Managers 2014-09-30 Add 39.82%0.03%$46.29 - $54.52 $ 46.4-5%208125
David Dreman 2014-09-30 New Buy0.01%$46.29 - $54.52 $ 46.4-5%1328
HOTCHKIS & WILEY 2014-06-30 Add 13358.6%0.93%$51.55 - $56.39 $ 46.4-14%4949118
PRIMECAP Management 2014-06-30 Reduce -43.82%0.25%$51.55 - $56.39 $ 46.4-14%5156449
John Rogers 2014-06-30 Add 49.33%0.21%$51.55 - $56.39 $ 46.4-14%988772
Charles Brandes 2014-06-30 Add 15.52%0.21%$51.55 - $56.39 $ 46.4-14%2500048
James Barrow 2014-06-30 New Buy0.02%$51.55 - $56.39 $ 46.4-14%270900
John Hussman 2014-03-31 Reduce -23.61%0.38%$50.9 - $56.66 $ 46.4-14%323500
John Rogers 2014-03-31 Add 57.21%0.16%$50.9 - $56.66 $ 46.4-14%662150
Vanguard Health Care Fund 2014-03-31 Sold Out 0.11%$50.9 - $56.66 $ 46.4-14%0
NWQ Managers 2014-03-31 Reduce -28.91%0.03%$50.9 - $56.66 $ 46.4-14%148800
HOTCHKIS & WILEY 2014-03-31 New Buy0.01%$50.9 - $56.66 $ 46.4-14%36773
John Hussman 2013-12-31 Add 1702.13%1.51%$49.31 - $53.68 $ 46.4-10%423500
John Rogers 2013-12-31 Add 208.93%0.19%$49.31 - $53.68 $ 46.4-10%421201
Charles Brandes 2013-12-31 Add 13.11%0.16%$49.31 - $53.68 $ 46.4-10%2145461
Vanguard Health Care Fund 2013-12-31 Reduce -55.18%0.14%$49.31 - $53.68 $ 46.4-10%644881
Joel Greenblatt 2013-12-31 New Buy0.11%$49.31 - $53.68 $ 46.4-10%83452
Warren Buffett 2013-12-31 Sold Out 0.02%$49.31 - $53.68 $ 46.4-10%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on GlaxoSmithKline PLC

Diamond Hill Capital Comments on GlaxoSmithKline PLC - Oct 17, 2014

We eliminated our position in GlaxoSmithKline PLC (GSK) due to concerns that the company will not be able to preserve the recent level of revenue or profitability generated by its respiratory franchise. Despite its development of high efficacy next generation respiratory drugs that have come to market in advance of Advair losing patent protection, the company is facing extreme pricing pressure from health care payors. Diversified machinery manufacturer Dover Corp. was eliminated as the stock price approached our estimate of intrinsic value.

From Diamond Hill Capital (Trades, Portfolio)'s Select Fund Third Quarter 2014 Commentary.

Check out Diamond Hill Capital latest stock trades

Diamond Hill Capital Comments on GlaxoSmithKline PLC - Jun 26, 2014

Global pharmaceutical company GlaxoSmithKline PLC (GSK) has several attractive franchises and pipeline drug candidates that have the potential to add significant value.



From Diamond Hill Capital's Select Fund Commentary – First Quarter 2014.



Check out Diamond Hill Capital latest stock trades

Top Ranked Articles about GlaxoSmithKline PLC

Irving Kahn Buys Stake in GlaxoSmithKline During Q3 2014
During the third quarter, Irving Kahn (Trades, Portfolio) of Kahn Brothers added only one position to the portfolio, and increased his holdings in just two companies. The majority of his activity was reducing his positions in 13 companies. Read more...
Diamond Hill Capital Comments on GlaxoSmithKline PLC
We eliminated our position in GlaxoSmithKline PLC (GSK) due to concerns that the company will not be able to preserve the recent level of revenue or profitability generated by its respiratory franchise. Despite its development of high efficacy next generation respiratory drugs that have come to market in advance of Advair losing patent protection, the company is facing extreme pricing pressure from health care payors. Diversified machinery manufacturer Dover Corp. was eliminated as the stock price approached our estimate of intrinsic value. Read more...
Guru Stocks at 52-Week Lows: PFE, GSK, VOD, EC, MFG
According to GuruFocus list of 52-week lows, these Guru stocks have reached their 52-week lows. Read more...
A Look at the Week's Top Dividend Growers
During the past week, GuruFocus recognized four companies as dividend growers. In order to be qualified for this list, the company had to: Read more...
Diamond Hill Capital Comments on GlaxoSmithKline PLC
Global pharmaceutical company GlaxoSmithKline PLC (GSK) has several attractive franchises and pipeline drug candidates that have the potential to add significant value. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 17.30
GSK's P/E(ttm) is ranked higher than
92% of the 939 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 43.60 vs. GSK: 17.30 )
GSK' s 10-Year P/E(ttm) Range
Min: 10.16   Max: 40.41
Current: 17.3

10.16
40.41
P/B 14.11
GSK's P/B is ranked higher than
50% of the 939 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.52 vs. GSK: 14.11 )
GSK' s 10-Year P/B Range
Min: 5.48   Max: 14.11
Current: 14.11

5.48
14.11
P/S 3.05
GSK's P/S is ranked higher than
76% of the 939 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.92 vs. GSK: 3.05 )
GSK' s 10-Year P/S Range
Min: 1.94   Max: 4.21
Current: 3.05

1.94
4.21
PFCF 20.58
GSK's PFCF is ranked higher than
94% of the 939 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. GSK: 20.58 )
GSK' s 10-Year PFCF Range
Min: 8.21   Max: 41.33
Current: 20.58

8.21
41.33
EV-to-EBIT 16.21
GSK's EV-to-EBIT is ranked higher than
87% of the 939 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.45 vs. GSK: 16.21 )
GSK' s 10-Year EV-to-EBIT Range
Min: 7.7   Max: 240.2
Current: 16.21

7.7
240.2
PEG 6.96
GSK's PEG is ranked higher than
85% of the 939 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. GSK: 6.96 )
GSK' s 10-Year PEG Range
Min: 0.23   Max: 426.6
Current: 6.96

0.23
426.6
Shiller P/E 16.81
GSK's Shiller P/E is ranked higher than
95% of the 939 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 141.81 vs. GSK: 16.81 )
GSK' s 10-Year Shiller P/E Range
Min: 10.59   Max: 20.59
Current: 16.81

10.59
20.59
Current Ratio 0.97
GSK's Current Ratio is ranked lower than
52% of the 882 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.42 vs. GSK: 0.97 )
GSK' s 10-Year Current Ratio Range
Min: 0.97   Max: 1.78
Current: 0.97

0.97
1.78
Quick Ratio 0.69
GSK's Quick Ratio is ranked lower than
53% of the 882 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.83 vs. GSK: 0.69 )
GSK' s 10-Year Quick Ratio Range
Min: 0.68   Max: 1.42
Current: 0.69

0.68
1.42

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 5.71
GSK's Dividend Yield is ranked higher than
99% of the 517 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.35 vs. GSK: 5.71 )
GSK' s 10-Year Dividend Yield Range
Min: 2.72   Max: 5.91
Current: 5.71

2.72
5.91
Dividend Payout 0.93
GSK's Dividend Payout is ranked higher than
99% of the 939 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.28 vs. GSK: 0.93 )
GSK' s 10-Year Dividend Payout Range
Min: 0.38   Max: 4.69
Current: 0.93

0.38
4.69
Dividend growth (3y) 6.40
GSK's Dividend growth (3y) is ranked higher than
81% of the 370 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.20 vs. GSK: 6.40 )
GSK' s 10-Year Dividend growth (3y) Range
Min: -12.6   Max: 20.8
Current: 6.4

-12.6
20.8
Yield on cost (5-Year) 7.81
GSK's Yield on cost (5-Year) is ranked higher than
97% of the 526 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.44 vs. GSK: 7.81 )
GSK' s 10-Year Yield on cost (5-Year) Range
Min: 3.73   Max: 8.1
Current: 7.81

3.73
8.1
Share Buyback Rate 1.40
GSK's Share Buyback Rate is ranked higher than
90% of the 605 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -1.30 vs. GSK: 1.40 )
GSK' s 10-Year Share Buyback Rate Range
Min: 3.6   Max: -20
Current: 1.4

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.51
GSK's Price/DCF (Projected) is ranked higher than
90% of the 939 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 11.94 vs. GSK: 1.51 )
GSK' s 10-Year Price/DCF (Projected) Range
Min: 0.97   Max: 3.75
Current: 1.51

0.97
3.75
Price/Median PS Value 1.05
GSK's Price/Median PS Value is ranked higher than
81% of the 939 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.31 vs. GSK: 1.05 )
GSK' s 10-Year Price/Median PS Value Range
Min: 0.69   Max: 2.57
Current: 1.05

0.69
2.57
Earnings Yield (Greenblatt) 6.20
GSK's Earnings Yield (Greenblatt) is ranked higher than
87% of the 878 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. GSK: 6.20 )
GSK' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.4   Max: 12.9
Current: 6.2

0.4
12.9
Forward Rate of Return (Yacktman) 5.57
GSK's Forward Rate of Return (Yacktman) is ranked higher than
80% of the 707 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.06 vs. GSK: 5.57 )
GSK' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 2.6   Max: 68.7
Current: 5.57

2.6
68.7

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:JNJ, PFE, RHHBY, NVS, ABT » details
Traded in other countries:GSK.UK, GLAXF.USA, GS7A.Germany, GS7.Germany, GSK N.Mexico, GSK.Argentina
GlaxoSmithKline PLC incorporated in United Kingdom. The Company creates, discoveres, develops, manufactures and markets pharmaceutical products including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company's principal pharmaceutical products include medicines in the following therapeutic areas: respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, oncology and emesis, dermatology, rare diseases, immuno-inflammation, vaccines and HIV. The Company is a science-led global healthcare company that researches and develops a broad range of innovative products in three primary areas of pharmaceuticals, vaccines and consumer healthcare. Its Pharmaceuticals business develops and makes medicines to treat a broad range of acute and chronic diseases. Its portfolio is made up of both patent-protected and off patent medicines. Its products include treatment for Infectious Diseases, Cancer, Epilepsy, Heart Disease, Asthma and Chronic obstructive pulmonary disease, and HIV/AIDS. Its Vaccine business has approximately 900 million doses distributed to 170 countries in 2012. It produces paediatric and adult vaccines to prevent a range of infectious diseases including: Hepatitis A and B, Diphtheria, Tetanus and Whooping cough, Measles, Mumps and Rubella, Polio, Typhoid, Influenza, Bacterial Meningitis. The consumer healthcare business, markets consumer health products based on scientific innovation. Its products main categories are: Oral care, Nutritional, Total wellness, and Skin health. Its barands include Sensodyne, Panadol and Horlicks. Its drinks brands are Lucozade and Ribena. The Oral Care brands, alli and Abreva.
» More Articles for GSK

Headlines

Articles On GuruFocus.com
Jeff Auxier Buys Berkshire Hathaway in Third Quarter Nov 18 2014 
Irving Kahn Starts New Position In GlaxoSmithKline Nov 13 2014 
Irving Kahn Buys Stake in GlaxoSmithKline During Q3 2014 Nov 12 2014 
Kahn Brothers' Third Quarter Numbers Nov 07 2014 
Tweedy Browne Global Value Fund's Top Picks for Q3 Oct 21 2014 
Diamond Hill Capital Comments on GlaxoSmithKline PLC Oct 17 2014 
Dodge & Cox’ Stock Fund Third Quarter 2014 Commentary Oct 16 2014 
Ebola: Is The Cure Out There? Oct 14 2014 
Guru Stocks at 52-Week Lows: GE, BHP, TOT, BP, GSK Oct 12 2014 
Guru Stocks at 52-Week Lows: BHP, GSK, UTX, SAP, TEF Sep 30 2014 

More From Other Websites
Is GlaxoSmithKline plc’s Dividend Safe? Nov 21 2014
Will GlaxoSmithKline plc Be Back To Growth By 2016? Nov 20 2014
GlaxoSmithKline plc Is Best In Class When It Comes To Affordable Medicine Nov 19 2014
The Top Performing And Yielding Dividend Funds Nov 18 2014
Good News From A Failed Digital Health Randomized Clinical Trial: It Was Performed Nov 18 2014
Director/PDMR Shareholding Nov 18 2014
Director/PDMR Shareholding Nov 14 2014
Director/PDMR Shareholding- Amendment Nov 14 2014
Why GlaxoSmithKline plc And HSBC Holdings plc Can Be The FTSE 100′s Stars Of 2015! Nov 14 2014
Europe shares open higher with positive GDP figures Nov 14 2014
Is A Boston University Professor's Plan For Lower Drug Costs Viable? Nov 13 2014
GlaxoSmithKline plc Is Working Hard To Unlock Value For Investors Nov 13 2014
Ebola To Have A Global Burden Of $5.9 Billion By End Of 2016 Nov 12 2014
Blocklisting Interim Review Nov 12 2014
Insys Q3 Beats Estimates, Helping Stock Rebound Nov 11 2014
The Inaccurate And Unfair WHO Attack On Pharma Ebola Efforts Nov 10 2014
Director/PDMR Shareholding Nov 10 2014
AstraZeneca plc And GlaxoSmithKline plc Are Strong Buys, But For Very Different Reasons Nov 10 2014
Director/PDMR Shareholding Nov 07 2014
Why Forecasts Are Falling At GlaxoSmithKline plc Nov 07 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK